Figure 2.
Survival curves of 385 patients with MCL experiencing late POD divided according to second-line treatment. (A) PFS from time of second-line therapy (PFS-2) of BTKi (median not reached) vs CIT (median, 26 months). (B) Overall survival from time of second-line therapy (OS-2) of BTKi (median, 88 months) vs CIT (median, 56 months).

Survival curves of 385 patients with MCL experiencing late POD divided according to second-line treatment. (A) PFS from time of second-line therapy (PFS-2) of BTKi (median not reached) vs CIT (median, 26 months). (B) Overall survival from time of second-line therapy (OS-2) of BTKi (median, 88 months) vs CIT (median, 56 months).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal